Smith & Nephew SNATS, Inc. which can be found using ticker (SNN) have now 3 confirmed analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price High/Low ranges between 36 and 32 with the average target price sitting at $34.33. Now with the previous closing price of $28.53 and the analysts are correct then there would likely be a percentage uptick in value of 20.3%. Also worth taking note is the 50 day moving average now sits at $28.52 and the 200 moving average now moves to $26.53. The total market capitalization for the company now stands at $12,499m. Find out more information at: https://www.smith-nephew.com
The potential market cap would be $15,040m based on the market consensus.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. The company operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products, including instruments, technologies, and implants to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
The company has a dividend yield of 2.63% with the ex dividend date set at 30-3-2023 (DMY).
Other points of data to note are a P/E ratio of 56.16, revenue per share of 11.96 and a 3.98% return on assets.
